Stryker Corporation (SYK)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Stryker Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 325.70 $ — 39% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 17.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 32
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 15.01 | 14.90 – 15.07 | 27,290 | 10.1% | 26 |
| 12/31/2027 | 16.76 | 16.46 – 17.08 | 29,600 | 11.7% | 27 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.41 | -52.50 | 6,436 | 10.70 | 8.50 | 1,931 | 1,665 |
| 2025: Q1 | 1.69 | -17.30 | 5,866 | 11.90 | 11.10 | 250 | 127 |
| 2025: Q2 | 2.29 | 6.90 | 6,022 | 11.10 | 14.70 | 1,111 | 928 |
| 2025: Q3 | 2.22 | 2.70 | 6,057 | 10.20 | 14.20 | 1,540 | 1,353 |
| 2025: Q4 | 2.20 | 55.30 | 7,171 | 11.40 | 11.80 | 2,143 | 1,875 |
| 2026: Q1 | 1.93 | 13.90 | 6,020 | 2.60 | 12.40 | 581 | 415 |
| 2026: Q2 | 3.30 | 44.10 | 6,589 | 9.40 | 19.40 | 1,261 | 1,059 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 11,325 | 2,577 | 1,647 | 4.35 | 1,915 | 9,550 | 20,435 |
| 2017 | 12,444 | 2,767 | 1,020 | 2.68 | 1,559 | 9,994 | 22,183 |
| 2018 | 13,601 | 3,104 | 3,553 | 9.34 | 2,610 | 11,730 | 27,229 |
| 2019 | 14,884 | 3,388 | 2,083 | 5.48 | 2,191 | 12,807 | 30,167 |
| 2020 | 14,351 | 3,028 | 1,599 | 4.20 | 3,277 | 13,084 | 34,330 |
| 2021 | 17,108 | 3,763 | 1,994 | 5.22 | 3,263 | 14,877 | 34,631 |
| 2022 | 18,449 | 3,734 | 2,358 | 6.17 | 2,624 | 16,616 | 36,884 |
| 2023 | 20,498 | 4,281 | 3,165 | 8.25 | 3,711 | 18,593 | 39,912 |
| 2024 | 22,595 | 5,061 | 2,993 | 7.76 | 4,242 | 20,634 | 42,971 |
| 2025 | 25,116 | 4,889 | 3,246 | 8.49 | 5,044 | 22,420 | 47,844 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Stryker Corporation ist ein Medizintechnikunternehmen in den USA und international. Es ist in zwei Segmenten tätig: MedSurg and Neurotechnology sowie Orthopaedics.
| Employees | 56,000 |
|---|---|
| Headquarters | Portage, MI |
| Address | 1941 Stryker Way, 49002 Portage, United States |
| Phone | (269) 385-2600 |
| Website | stryker.com |
| IPO Date | 1. Feb 1988 |
| ISIN | US8636671013 |
| Stock Split | 2:1 on 05/17/2004 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Kevin A. Lobo | Chairman & CEO | 1965 |
| Spencer S. Stiles | President & COO | 1977 |
| Preston W. Wells | VP & CFO | 1977 |
| Viju S. Menon | Group President of Global Quality & Operations | 1968 |
| J. Andrew Pierce | Group President of MedSurg & Neurotechnology | 1974 |
| William E. Berry Jr. | VP & Chief Accounting Officer | 1966 |
| Robert C. Cohen | CTO and VP of Global R&D - Joint Replacement | – |
| Debra S. King | VP and Chief Digital & Information Officer | 1972 |
| Nick Mead | Vice President of Investor Relations | – |
| Robert S. Fletcher | VP & Chief Legal Officer | 1971 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.